|Table of Contents|

The clinical effect of pelvic peritonectomy in the surgical treatment of advanced epithelial ovarian cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 20
Page:
3910-3915
Research Field:
Publishing date:

Info

Title:
The clinical effect of pelvic peritonectomy in the surgical treatment of advanced epithelial ovarian cancer
Author(s):
MENG Lingting; YANG Bin; ZHAO Xixia; XU Zhao; LEI Lei
Shaanxi Provincial Tumor Hospital，Shaanxi Xi'an 710061,China.
Keywords:
total pelvic peritonectomy; advanced epithelial ovarian cancer; surgical procedure; surgical satisfaction; chemotherapy cycles; post operative complications
PACS:
R737.31
DOI:
10.3969/j.issn.1672-4992.2024.20.017
Abstract:
Objective:To analyze the clinical efficacy of pelvic peritonectomy (PP) in the surgery of advanced epithelial ovarian cancer (EOC).Methods:The clinical data of 45 EOC patients (PP-CRS group) who underwent cytoreductive surgery (CRS) with PP in our hospital from January 2017 to January 2020 were retrospectively analyzed.Meanwhile,45 EOC patients (traditional CRS group) who underwent traditional CRS during the same period were selected as the control group.The clinical pathological data and surgery-related data of the two groups were compared to evaluate the clinical efficacy of PP in the surgery of advanced EOC.Results:The complete cytoreduction score (CC score) of the PP-CRS group was significantly higher than that of the traditional CRS group (P＜0.05).There was also a significant difference in the number of first-line chemotherapy cycles between the two groups,with the PP-CRS group having fewer chemotherapy cycles than the traditional CRS group (P＜0.05).There was no significant difference between the two groups in terms of age,body mass index (BMI),pathological type,pathological grade,pathological stage,neoadjuvant chemotherapy ratio,Eastern Cooperative Oncology Group performance status (ECOG score),3-year progression-free survival (PFS),operation time,blood loss,hospital stay,time to first postoperative chemotherapy and surgery complications (P＞0.05).Conclusion:PP-CRS is relatively simple to operate and has a low incidence of postoperative complications,which also can improve the surgical satisfaction and reduce the total number of first-line chemotherapy cycles.Therefore,PP-CRS has clinical significance for the surgical treatmentof advanced EOC and is worthy of promotion in clinical practice.

References:

［1］中国抗癌协会妇科肿瘤专业委员会.卵巢恶性肿瘤诊断与治疗指南(2021年版)［J］.中国癌症杂志， 2021,31(6):490-500. Chinese Anti-Cancer Association gynecological tumor professional committee.Guidelines for diagnosis and treatment of ovarian malignancy (2021 edition)［J］.Chinese Journal of Cancer,2021,31(6):490-500.
［2］ 中华医学会妇科肿瘤学分会.卵巢癌PARP抑制剂临床应用指南(2022版)［J］.现代妇产科进展,2022,31(8):561-572. Chinese Society of Gynecologic Oncology.Guidelines for clinical application of PARP inhibitors in ovarian cancer (2022 edition)［J］.Advances in Modern Obstetrics and Gynecology,2022,31(8):561-572.
［3］ 张国楠,刘红,石宇.晚期卵巢上皮性癌广泛性腹膜切除术的理论基础与临床应用价值［J］.中华妇产科杂志,2019,54(6):417-420. ZHANG GN,LIU H,SHI Y.The theoretical basis and clinical application value of extensive peritoneectomy for advanced epithelial ovarian cancer ［J］.Chinese Journal of Obstetrics and Gynecology,2019,54(6):417-420.
［4］ TOZZI R,GIANNICE R,CIANCI S,et al.Neo-adjuvant chemotherapy does not increase the rate of complete resection and does not significantly reduce the morbidity of Visceral-Peritoneal Debulking (VPD) in patients with stage IIIC-IV ovarian cancer［J］.Gynecol Oncol,2015，138:252-258.
［5］ EINENKEL J,OTT R,HANDZEL R,et al.Characteristics and management of diaphragm involvement in patients with primary advanced-stage ovarian,fallopian tube,or peritoneal cancer［J］.International Journal of Gynecological Cancer,2009,19(7):1288-1297.
［6］ VAZQUEZ VDL,SUGARBAKER PH.Total anterior parietal peritonectomy［J］.Wiley Subscription Services,Inc.A Wiley Company,2003,83(4):261-263.
［7］ HUDSON CN.A radical operation for fixed ovarian tumours［J］.BJOG:An International Journal of Obstetrics & Gynaecology,1968,75(11)：1155-1160.
［8］ 连利娟,林巧稚.妇科肿瘤学［M］.2版.北京:北京人民卫生出版社,1982:526-532. LIAN LJ,LIN Qiaozhi.Gynecologic oncology ［M］.2nd edition.Beijing:Beijing People's Medical Publishing House,1982:526-532.
［9］ WARTON JT,EDWARDS CL,STRINGER CA.Techniques for surgical staging and cytoreductive surgery［J］.Clinical Obstetrics & Gynecology,1985,28(4):800-805.
［10］ XIANG L,YE S,YANG H.Total pelvic peritonectomy for ovarian cancer with extensive peritoneal carcinomatosis in pelvic cavity［J］.Gynecol Oncol,2019,154(3):651-652.
［11］ 刘红,石宇,张国楠,等.Ⅲc期卵巢上皮性癌“卷地毯”式肿瘤细胞减灭术的技术要点与安全性分析［J］.中华妇产科杂志,2020,55(8):417-418. LIU H,SHI Y,ZHANG GN,et al.Key technical points and safety analysis of rolling carpet tumor cell reduction for stage III ovarian epithelial cancer ［J］.Chinese Journal of Obstetrics and Gynecology,2020,55(8):417-418.
［12］ DENNIS S CHI,ROBERT G BRISTOW.In response to:Establishing evidence for change in ovarian cancer surgery-Proposing clinical trials of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in ovarian cancer peritoneal carcinomatosis［J］.Gynecologic Oncology,2009,115(1):168-169.
［13］ GIDED KC,KIESER K,DODGE J,et al.Who should operate on patientswith ovarian cancer? An evidence-based review［J］.Gynecologic Oncology,2005,99(2):447-461.
［14］ BURLESON KM,BOENTE MP,PAMBUCCIAN SE,et al.Disaggregation and invasion of ovarian carcinoma ascites spheroids［J］.Journal of Translational Medicine,2006,4(1):1-16.
［15］ SYLVAIN L,ESPERANC E,BACHVAROVA M,et al.Global gene expression analysis of early response to chemotherapy treatment in ovarian cancer spheroids［J］.Bmc Genomics,2008,9(1):99-102.
［16］ ENGELEN MJA,KOS HE,WILLEMSE PHB,et al.Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma.［J］.WILEY,2006,106(3):216-223.

Memo

Memo:
-
Last Update: 1900-01-01